Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
2,530 people get BAX articles and Market Currents by email alert.
Get email alerts on BAX »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
Baxter International Inc. - Special CallTue, May 7
-
Business Wire (May 7, 2013)
-
Business Wire (May 6, 2013)
-
-
Business Wire (Apr 25, 2013)
-
-
Business Wire (Apr 24, 2013)
-
Business Wire (Apr 24, 2013)
-
-
Business Wire (Apr 18, 2013)
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
Why We Like Baxter's DividendValuentum • Thu, Oct 25, 2012 -
-
-
-
Baxter Still Defensive, But Is Now The Time For Offense?Stephen Simpson • Tue, May 15, 2012 -
Baxter Earnings PreviewZacks Investment Research • Tue, Apr 17, 2012 -
-
Baxter's A Buy For Growth, Cash Flow, And Rising DividendsIngrid Hendershot • Tue, Mar 13, 2012 -
-
-
-
-
Baxter International Inc. - Special CallTue, May 7
-
Baxter International Q2 2010 Earnings Call TranscriptThu, Jul 22, 2010
-
Baxter International Inc. Q1 2010 Earnings Call TranscriptThu, Apr 22, 2010
-
Baxter International Inc. Q4 2009 Earnings Call TranscriptThu, Jan 28, 2010
-
Baxter International Inc. Q3 2009 Earnings Call TranscriptThu, Oct 15, 2009
-
Baxter International Inc. Q2 2009 Earnings Call TranscriptThu, Jul 16, 2009
-
at CNBC.com (Fri, 6:02PM)
-
at CNBC.com (May 7, 2013)
-
Business Wire (May 7, 2013)
-
Business Wire (May 6, 2013)
-
Business Wire (Apr 25, 2013)
-
Business Wire (Apr 24, 2013)
-
Business Wire (Apr 24, 2013)
-
Business Wire (Apr 18, 2013)
-
at CNBC.com (Apr 17, 2013)
-
at MarketWatch.com (Apr 8, 2013)
-
Business Wire (Mar 27, 2013)
-
Business Wire (Feb 27, 2013)
-
Business Wire (Feb 19, 2013)
-
Business Wire (Feb 7, 2013)
-
at CNBC.com (Jan 29, 2013)
BAX vs. ETF Alternatives
Company Description
Baxter develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, December 4, 2012, 9:07 AM More on Baxter (BAX) / Gambro deal: the acquisition, Baxter's largest ever, combines the second and third largest manufacturers of dialysis equipment, so it could arouse antitrust concerns. Baxter expects synergies of $300M a year by 2017, but says the deal will cut adjusted EPS by $0.10-$0.15 next year and be neutral or add to earnings in 2014, and then add to profit after that. (Webcast) (PR) Comment! [M&A, Healthcare, Top Stories, Earnings]
- Tuesday, December 4, 2012, 7:13 AM As tipped about 10 days ago, Baxter International (BAX) inks an agreement to buy Sweden's Gambro for $4B. The acquisition should give Baxter a more complete line of dialysis products. Baxter shares leaped around 5% on the day of the initial leak of the talks, but have since given up those gains. (PR) Comment! [Healthcare, M&A]
- Friday, November 23, 2012, 10:35 AM Baxter International (BAX +1.4%) is in talks on a deal to buy Swedish medical-equipment maker Gambro for roughly $4B. Though still in its early stages, the companies are aiming to complete a deal within the next two to three weeks. Comment! [Healthcare, On the Move, M&A]
- Wednesday, November 14, 2012, 12:32 PM Baxter (BAX -0.2%) gets initiated at Bernstein this morning with an Outperform, asserting that the threat from Biogen's (BIIB) late-stage hemophilia drug research to BAX's dominant drug, Advate, is overblown. The firm says patients are reluctant to switch treatments, and the area where BIIB's drug looks strongest - treating sudden bleeding episodes - accounts for just 25% of Advate's US sales. Additionally, BAX also has late-stage data on an Alzheimer's drug due next year. Comment! [Healthcare]
- Tuesday, November 13, 2012, 12:10 PM Baxter International Inc. (BAX) declares $0.45/share quarterly dividend, in line with previous. Forward yield 2.74%. For shareholders of record Dec. 7. Payable Jan 3. Ex-div Dec. 5. (PR) Comment! [Dividends]
- Thursday, October 18, 2012, 7:04 AM Baxter (BAX): Q3 EPS of $1.14 in-line. Revenue of $3.48B (flat% Y/Y) misses by $40M. (PR) Comment! [Earnings, Healthcare]
- Thursday, October 18, 2012, 12:05 AM Notable earnings before Thursday’s open: BAX, BBT, BSX, BX, CY, DHR, DO, FCS, FITB, GPC, HBAN, KEY, LH, LUV, MS, NOK, NUE, PII, PM, PPG, SVU, TRV, UNP, USG, VZ Comment! [Earnings]
- Wednesday, October 17, 2012, 5:30 PM Notable earnings before Thursday’s open: BAX, BBT, BSX, BX, CY, DHR, DO, FCS, FITB, GPC, HBAN, KEY, LH, LUV, MS, NOK, NUE, PII, PM, PPG, SVU, TRV, UNP, USG, VZ 2 Comments [Earnings]
- Wednesday, September 19, 2012, 9:40 AM Baxter (BAX) agrees to pay Onconova Therapeutics $50M upfront for the European commercialization rights for rigosertib, a compound in Phase III trials for treating rare hematologic (blood) malignancies and in Phase II/III trials for pancreatic cancer. Baxter may also pay up to $515M in pre-commercial development and regulatory milestones, as well as sales milestones and royalties. (PR) Comment! [Healthcare]
- Wednesday, August 1, 2012, 7:24 PM Baxter (BAX) confirms it's received a complete response letter from the FDA delaying the approval of its investigational product HyQ. More specifically, the agency says it's seeking additional preclinical data focusing on issues related to non-neutralizing antibodies and the possible effects they have on reproduction, development and fertility. HyQ, which is in development with Halozyme Therapeutics (HALO), is a treatment that aims to allow physicians to tailor antibody drug therapy to the needs of patients with immune-system disorders. BAX -0.6%, HALO -54% AH. Comment! [Healthcare, On the Move]
- Wednesday, July 25, 2012, 12:49 PM In addition to raising its dividend by 34% this morning, Baxter International (BAX +2.9%) also approves a new $2B stock buyback program, as the health-care company looks to share the wealth and boost shareholder value. BAX has benefited recently on strong demand for its hemophilia and immunodeficiency products, and because of its product focus on life-threatening ailments and injuries, the company has been less impacted by the slowdown in health-care spending than its peers. 1 Comment [Healthcare, On the Move]
- Wednesday, July 25, 2012, 9:48 AM Baxter International (BAX) declares $0.45/share quarterly dividend, 34% increase from prior dividend of $0.335. Forward yield 3.15%. For shareholders of record Sep 07. Payable Oct 01. Ex-div date Sep 05. (PR) Comment! [Dividends]
- Thursday, July 19, 2012, 10:42 AM More on Baxter (BAX +1%) Q2: net profit rises to $661M from $615M despite forex hurting revenue growth. Announces deal with Holland's Sanquin Blood Supply Foundation to support the growth of Baxter's plasma-derived treatments. Guidance: Q3 EPS $1.12-$1.14 vs consensus of $1.16, sales growth of 1% vs. 2%; FY $4.50-$4.56 vs. $4.49-$4.57 prior forecast and $4.52 consensus. Comment! [Earnings, Healthcare]
- Thursday, July 19, 2012, 7:13 AM Baxter International (BAX): Q2 EPS of $1.12 beats by $0.01. Revenue of $3.57B (+1.0% Y/Y) beats by $40M. (PR) Comment! [Earnings, Healthcare]
- Thursday, July 19, 2012, 12:05 AM Notable earnings before Thursday’s open: ADS, BAX, BBT, BX, CY, DGX, DHR, DO, FCS, FCX, FITB, GPC, HBAN, JCI, KEY, LUV, MS, NOK, NUE, NVS, PM, SHW, SWY, TCB, TRV, TSM, TXT, UNH, UNP, VZ Comment! [Earnings]
- Wednesday, July 18, 2012, 5:30 PM Notable earnings before Thursday’s open: ADS, BAX, BBT, BX, CY, DGX, DHR, DO, FCS, FCX, FITB, GPC, HBAN, JCI, KEY, LUV, MS, NOK, NUE, NVS, PM, SHW, SWY, TCB, TRV, TSM, TXT, UNH, UNP, VZ Comment! [Earnings]
-
- View all 0 replies
-
Holly Thompson
Goldman maintains Buy rating for Baxter (BAX) given its attractive valuation, favorable geographic mix and strong new product flow. - View all 0 replies
-
Jacob Wolinsky
Tweedy Browne Named Portfolio Managers Of The Year http://bit.ly/yp1o4v $MORN $TGBVX $DEO $JNJ $TOT $WFC $BAX - View all 0 replies
-
- View all 0 replies
-
Chuck Carnevale
$BAX - What do the earnings & price correlated F.A.S.T. Graphs show us regarding Baxer? http://bit.ly/sBznMv - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Michael Bryant
"Drug firms told to pay $162M in hepatitis C case." Negative for Teva (TEVA), Baxter (BAX), and McKesson (MCK). http://yhoo.it/mQUS7Y - View all 0 replies
LATEST REPLIES